CDEK
← All drugs Report issue

agen2034

mAbexperimental

Clinical trial activity

10 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Apr 11, 2017 (NCT03104699)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • agen2034

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06095674Phase 1Jan 31, 2024Agenus Inc., Dutch Cancer Society, University of Amsterdam
NCT05205330Phase 1/Phase 2 (Phase 2)Nov 23, 2021Agenus Inc., IRCCS Istituto Nazionale dei Tumori, Rottapharm
NCT04607200Phase 2Dec 31, 2020Agenus Inc.
NCT04430036Phase 2Aug 31, 2020University of Texas, San Antonio
NCT04028063Phase 2Aug 31, 2019Agenus Inc., National Cancer Institute (NCI), University of Colorado, Denver
NCT03894215Phase 2May 31, 2019Agenus Inc.
NCT03860272Phase 1Mar 20, 2019Agenus Inc.
NCT03495882Phase 1/Phase 2 (Phase 2)Dec 18, 2017Agenus Inc., ICON
NCT03104699Phase 1/Phase 2 (Phase 2)Apr 11, 2017Agenus Inc.
NCT06751524N/A—Agenus Inc.
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Agenus Inc.For profit9632017
Dutch Cancer SocietyAcademic/Hospital1012024
ICONFor profit1012017
IRCCS Istituto Nazionale dei TumoriAcademic/Hospital1012021
National Cancer Institute (NCI)Government1012019
RottapharmFor profit1112021
University of AmsterdamAcademic/Hospital1112024
University of Colorado, DenverAcademic/Hospital1112019
University of Texas, San AntonioAcademic/Hospital1112020
9 organizations
Page 1 / 1